Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2025; 21
DOI: 10.1055/s-0045-1808048
UROLOGIC TUMORS – PROSTATE
1901
POSTER PRESENTATION

Low-dose versus standard-dose abiraterone in metastatic castration-resistant prostate cancer post-docetaxel: randomized controlled trial in Brazil (Dumont)

Ana Rafaela Nascimento e Bouças
,
Monalisa Ceciliana Freitas Moreira de Andrade
,
Rodrigo Jerônimo de Araújo
,
Sulene Cunha Sousa Oliveira
,
Sofia Bezerra Rocha
,
Kleyton Santos Medeiros
,
Gabriela Miranda Sá
,
Aline Alves Soares
,
Luciana Câmara da Silva
,
Isa Leandro Soares
,
Menilla Maria Alves de Melo
,
Andrea Juliana Pereira de Santana Gomes
› Weitere Informationen
  Alle Artikel dieser Rubrik

Keywords

prostate neoplasm - castration-resistant prostate neoplasm - abiraterone acetate


Publikationsverlauf

Artikel online veröffentlicht:
06. Mai 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

Bibliographical Record
Ana Rafaela Nascimento e Bouças, Monalisa Ceciliana Freitas Moreira de Andrade, Rodrigo Jerônimo de Araújo, Sulene Cunha Sousa Oliveira, Sofia Bezerra Rocha, Kleyton Santos Medeiros, Gabriela Miranda Sá, Aline Alves Soares, Luciana Câmara da Silva, Isa Leandro Soares, Menilla Maria Alves de Melo, Andrea Juliana Pereira de Santana Gomes. Low-dose versus standard-dose abiraterone in metastatic castration-resistant prostate cancer post-docetaxel: randomized controlled trial in Brazil (Dumont). Brazilian Journal of Oncology 2025; 21.
DOI: 10.1055/s-0045-1808048